Abstract:Purpose: Neurofibromatosis type 1(NF1) and type 2(NF2) are both autosomal dominantly inherited disorders and originate from schwann cells. This study was done to investigate the genetic and proteomic profiles of the tumours.Methods: Mutational analyses of neurofibromatosis type 1 and type 2 genes (NF1 and NF2) in 15 NF1 and NF2 patients were carried out using Sanger sequencing. TMT-labeled spectrometry analysis was used to identify the proteome of neurofibromatosis type 1 and type 2 relative to nerve controls. Loss of heterozygosity were analysed for the candidate gene EPB41L3. Protein expression of tumour tissues/cultures was assessed by Western blots and/or immunofluorescence.Finds: DNA sequencing showed frequent mutations within NF1 or NF2 in the neurofibromatosis type 1 and type 2, respectively. 159 proteins were significantly differentially expressed in NF1 compared with normal nerves, and 180 proteins were significantly differentially expressed in NF2 compared with normal nerves. Among these, 11 were found commonly up-regulated and 30 down-regulated in both tumors. Among the commonly significantly down-regulated proteins in both tumors we consistently find EPB41L3.The EPB41L3 tumour suppressor showed the most significantly decreased expression, and existed predominantly at the cytoplasm of HEI193 and NF1 cell cultures. Western blot analysis identified the down-regulation in the NF1 and NF2 association with neurofibromin and merlin, respectively. LOH of EPB41L3 was more common among neurofibromatosis type 1(seen in 3 of 5 tumors, 60%) and least common among neurofibromatosis type 2 (2 of 10, 20%).Interpretation: Our data first get an insight into the common molecular mechanisms of neurofibroma, that indicates the potential role of EPB41L3 as a therapeutic target for this tumor syndrome.Funding Information: This work was supported by the National Natural Science Foundation of China (Grant No. 82171366 to Wei Chen; No. 82070541, 81600625, both to ML; 81771332, 81571184, both to CZ; 82172820 to JZ).and Grant No. 19ZR1447400 to Wei Chen. Jiangxi province outstanding poject (Grant No.20202ACBL216005 to Wei Chen); the Health Industry Clinical Research Project of Shanghai Municipal Health Commission (No. 20204125, to ML; No. 201840110, to SX); the Outstanding Leaders Training Program of Pudong Health Bureau of Shanghai (No. PWR12018-07, to CZ);the Key Discipline Construction Project of Pudong Health Bureau of Shanghai (No. PWZxk2017-23, to CZ); the Top-level Clinical Discipline Project of Shanghai Pudong (No. PWYgf2018-05, to CZ) .Declaration of Interests: The authors declare that they have no competing interests.Ethics Approval Statement: Informed written consent was obtained from all patients donating tissue. This study was approved by the Institutional Review Board of the ethics committee of The shanghai east Hospital affiliated to School of Medicine, Shanghai Tong Ji University.

Whole Exomes Sequencing For Neurofibromatosis Type I Patients Complicated With Gastrointestinal Stromal Tumors

Breast Cancer Risk and Germline Genomic Profiling of Women with Neurofibromatosis Type 1 Who Developed Breast Cancer.

Whole-exome sequencing of breast cancer, malignant peripheral nerve sheath tumor and neurofibroma from a patient with neurofibromatosis type 1

Gastrointestinal Stromal Tumors With Kit Mutation Coexisting With Wild-Type Gastrointestinal Stromal Tumors In A Patient With Neurofibromatosis Type 1

Gastrointestinal Stromal Tumours in Patients with Neurofibromatosis Type 1: A Case Report and Retrospective Review of 72 Cases

Proof of Concept for Genome Profiling of the Neurofibroma/Sarcoma Sequence in Neurofibromatosis Type 1

Next Generation Sequencing (NGS) in Wild Type GISTs.

Neurofibromatosis type 1 with multiple gastrointestinal stromal tumors: A case report

Proteomic and Genetic Analysis Reveals Loss of EPB41L3 Related to the Tumorigenesis of Neurofibromatosis Type 1 and Type 2

Multiple Gastrointestinal Stromal Tumors, Malignant Peripheral Nerve Sheath Tumor and Atypical Neurofibromatous Neoplasm With Uncertain Biologic Potential Developing in A Single Patient With Neurofibromatosis Type 1 Syndrome

Identification of Genomic Alterations in Sporadic Pancreatic Neurogenic Tumors.

Intratumoral KIT Mutational Heterogeneity and Recurrent KIT/ PDGFRA Mutations in KIT/PDGFRA Wild-Type Gastrointestinal Stromal Tumors

Cmar_a_280174 297..306

FGFR1 and NTRK3 actionable alterations in “Wild-Type” gastrointestinal stromal tumors

Targeted Deep Sequencing Reveals Unrecognized KIT Mutation Coexistent with NF1 Deficiency in GISTs.

Identification of a Novel FGFR2-KIAA1217 Fusion in Esophageal Gastrointestinal Stromal Tumours: A Case Report

Whole-exome sequencing analysis of mutation characteristics in recurrent or metastatic gastrointestinal stromal tumors

Jejunal gastrointestinal stromal tumor that developed in a patient with neurofibromatosis type 1: a case report

Chinese Pedigree with Hereditary Gastrointestinal Stromal Tumors: A Case Report and Literature Review

Case report: Neurofibromatosis type 1 gastrointestinal stromal tumor and small bowel adenocarcinoma with a novel germline NF1 frameshift mutation

Integrated genomic analysis of NF1-associated peripheral nerve sheath tumors: an updated biorepository dataset